NASDAQ:IMMU - Immunomedics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$22.57 +0.92 (+4.25 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$22.57
Today's Range$21.5378 - $22.60
52-Week Range$7.17 - $22.60
Volume2.29 million shs
Average Volume2.21 million shs
Market Capitalization$3.55 billion
P/E Ratio-27.86
Dividend YieldN/A
Beta1.6

About Immunomedics (NASDAQ:IMMU)

Immunomedics logoImmunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody; and a collaboration agreement with University of Wisconsin Carbone Cancer Center to expand IMMU-132 into prostate cancer. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IMMU
CUSIP45290710
Phone973-605-8200

Debt

Debt-to-Equity Ratio2.81
Current Ratio3.94
Quick Ratio3.94

Price-To-Earnings

Trailing P/E Ratio-27.86
Forward P/E Ratio-20.71
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.09 million
Price / Sales1,222.36
Cash FlowN/A
Price / CashN/A
Book Value$0.43 per share
Price / Book52.49

Profitability

EPS (Most Recent Fiscal Year)($0.81)
Net Income$-153,200,000.00
Net Margins-8,708.96%
Return on EquityN/A
Return on Assets-47.04%

Miscellaneous

Employees138
Outstanding Shares167,350,000

Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics (NASDAQ:IMMU) posted its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.06. The biopharmaceutical company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $4.27 million. The firm's revenue was down 61.5% compared to the same quarter last year. View Immunomedics' Earnings History.

What price target have analysts set for IMMU?

2 analysts have issued 12 month target prices for Immunomedics' shares. Their forecasts range from $15.00 to $27.00. On average, they expect Immunomedics' stock price to reach $21.00 in the next twelve months. View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest in April. As of April 30th, there was short interest totalling 28,420,435 shares, an increase of 0.1% from the April 13th total of 28,384,688 shares. Based on an average daily volume of 1,792,307 shares, the days-to-cover ratio is currently 15.9 days. Approximately 19.2% of the shares of the stock are sold short.

Who are some of Immunomedics' key competitors?

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:
  • Dr. David M. Goldenberg, Former Founder (Age 80)
  • Mr. Michael R. Garone, CFO, Principal Accounting Officer & VP of Fin. (Age 59)
  • Mr. Michael F. Pehl, Pres, CEO & Director (Age 53)
  • Ms. Phyllis Parker, Director of Admin.
  • Dr. Chau Cheng, Sr. Director of Investor Relations & Corp. Sec.

Has Immunomedics been receiving favorable news coverage?

Press coverage about IMMU stock has been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Immunomedics earned a news impact score of 0.22 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 47.88 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Immunomedics' major shareholders?

Immunomedics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.45%), Acuta Capital Partners LLC (3.50%), Palo Alto Investors LP (2.87%), Victory Capital Management Inc. (1.13%), Northern Trust Corp (0.76%) and Nexthera Capital LP (0.65%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark, Mary E Paetzold and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

Which major investors are selling Immunomedics stock?

IMMU stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, JPMorgan Chase & Co., Lyon Street Capital LLC, UBS Group AG, Jane Street Group LLC, Iguana Healthcare Management LLC, Highland Capital Management LP and BlackRock Inc.. Company insiders that have sold Immunomedics company stock in the last year include Brian A Markison, Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.

Which major investors are buying Immunomedics stock?

IMMU stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Nexthera Capital LP, Massachusetts Financial Services Co. MA, Rock Springs Capital Management LP, Sphera Funds Management LTD., University of Notre Dame DU Lac, Royal Bank of Canada and DekaBank Deutsche Girozentrale. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

How do I buy shares of Immunomedics?

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of IMMU stock can currently be purchased for approximately $22.57.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $3.55 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Immunomedics employs 138 workers across the globe.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]


MarketBeat Community Rating for Immunomedics (IMMU)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  398
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Immunomedics (NASDAQ:IMMU) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Immunomedics in the last 12 months. Their average twelve-month price target is $21.00, suggesting that the stock has a possible downside of 6.96%. The high price target for IMMU is $27.00 and the low price target for IMMU is $15.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.00$21.00$21.00$15.50
Price Target Upside: 6.96% downside15.96% upside15.96% upside32.93% upside

Immunomedics (NASDAQ:IMMU) Consensus Price Target History

Price Target History for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ:IMMU) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018Jefferies GroupBoost Price TargetBuy$22.00 ➝ $27.00MediumView Rating Details
7/24/2017CowenReiterated RatingOutperform$15.00LowView Rating Details
5/5/2017Wells Fargo & CoUpgradeMarket Perform ➝ OutperformHighView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Immunomedics (NASDAQ:IMMU) Earnings History and Estimates Chart

Earnings by Quarter for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ:IMMU) Earnings Estimates

2018 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.12)($0.12)($0.12)
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.19)($0.19)($0.19)

Immunomedics (NASDAQ IMMU) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q3 2018($0.15)($0.21)$4.27 million$0.50 millionViewN/AView Earnings Details
2/8/2018Q2 2018($0.10)($0.19)$0.90 million$0.60 millionViewN/AView Earnings Details
11/9/2017Q1 2018($0.10)($0.16)$0.90 million$0.69 millionViewN/AView Earnings Details
8/16/2017Q4 2017($0.12)($0.25)$0.75 million$0.64 millionViewN/AView Earnings Details
5/10/2017Q3 2017($0.13)($0.22)$0.90 million$1.32 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.13)($0.16)$0.70 million$0.38 millionViewListenView Earnings Details
11/2/2016Q117($0.14)($0.17)$0.70 million$0.74 millionViewN/AView Earnings Details
8/17/2016Q416($0.11)($0.17)$0.90 million$0.93 millionViewListenView Earnings Details
5/4/2016Q3($0.13)($0.15)$0.70 million$0.90 millionViewN/AView Earnings Details
2/3/2016Q216($0.14)($0.15)$1.40 million$0.67 millionViewN/AView Earnings Details
11/4/2015Q116($0.14)($0.16)$1.23 million$0.73 millionViewN/AView Earnings Details
8/19/2015Q415($0.13)($0.13)$1.13 million$2.40 millionViewListenView Earnings Details
5/6/2015Q3 2015($0.13)($0.13)$1.07 million$1.18 millionViewN/AView Earnings Details
2/4/2015Q215($0.13)($0.12)$1.73 million$1.00 millionViewN/AView Earnings Details
11/5/2014Q1 2015($0.12)($0.13)$1.18 million$1.07 millionViewN/AView Earnings Details
8/25/2014Q414($0.13)($0.13)$1.20 million$1.20 millionViewN/AView Earnings Details
5/7/2014Q3 2014($0.12)$0.02$1.13 million$1.15 millionViewN/AView Earnings Details
2/10/2014Q214($0.10)($0.10)$1.20 million$1.20 millionViewN/AView Earnings Details
11/4/2013Q1 2014($0.10)($0.05)$1.51 million$5.50 millionViewN/AView Earnings Details
8/22/2013Q4 2013($0.12)($0.09)$0.81 million$1.40 millionViewN/AView Earnings Details
5/8/2013Q3 2013($0.10)$0.11$0.97 million$1.70 millionViewN/AView Earnings Details
2/7/2013Q2 2013($0.09)($0.07)ViewN/AView Earnings Details
11/8/2012Q1 2013($0.08)($0.10)ViewN/AView Earnings Details
8/23/2012Q4 2012($0.08)($0.10)ViewN/AView Earnings Details
5/8/2012Q3 2012($0.08)($0.10)ViewN/AView Earnings Details
2/8/2012Q2 2012($0.08)$0.27ViewN/AView Earnings Details
11/4/2011Q1 2012($0.08)($0.07)ViewN/AView Earnings Details
8/24/2011Q4 2011($0.06)$0.03ViewN/AView Earnings Details
5/10/2011Q3 2011($0.06)($0.10)ViewN/AView Earnings Details
2/4/2011Q2 2011($0.08)($0.05)ViewN/AView Earnings Details
11/4/2010Q1 2011($0.07)($0.09)ViewN/AView Earnings Details
8/26/2010Q4 2010($0.08)$0.01ViewN/AView Earnings Details
5/10/2010Q3 2010($0.09)$0.05ViewN/AView Earnings Details
2/2/2010Q2 2010$0.03$0.01ViewN/AView Earnings Details
11/6/2009Q1 2010$0.43$0.42ViewN/AView Earnings Details
8/27/2009Q4 2009$0.01$0.01ViewN/AView Earnings Details
5/11/2009Q3 2009($0.01)$0.01ViewN/AView Earnings Details
2/9/2009Q2 2009($0.01)$0.04ViewN/AView Earnings Details
11/7/2008Q1 2009($0.03)ViewN/AView Earnings Details
8/28/2008Q4 2008($0.08)($0.09)ViewN/AView Earnings Details
5/7/2008Q3 2008($0.08)ViewN/AView Earnings Details
2/7/2008Q2 2008($0.09)($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Immunomedics (NASDAQ:IMMU) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Immunomedics (NASDAQ IMMU) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.80%
Institutional Ownership Percentage: 74.12%
Insider Trading History for Immunomedics (NASDAQ:IMMU)
Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ IMMU) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/7/2018David M GoldenbergDirectorSell20,000$17.50$350,000.001,774,285View SEC Filing  
3/5/2018David M GoldenbergDirectorSell40,000$17.24$689,600.001,774,285View SEC Filing  
2/28/2018David M GoldenbergDirectorSell17,729$17.09$302,988.611,774,285View SEC Filing  
11/20/2017Brian A MarkisonDirectorSell8,390$11.89$99,757.1099,178View SEC Filing  
11/15/2017Behzad AghazadehInsiderBuy1,325,000$10.47$13,872,750.00View SEC Filing  
11/14/2017Venbio Select Advisor LlcDirectorBuy1,150,000$10.39$11,948,500.00View SEC Filing  
9/1/2017David M. GoldenbergInsiderSell20,000$12.64$252,800.00View SEC Filing  
8/28/2017Cynthia L. GoldenbergDirectorSell40,000$10.72$428,800.00View SEC Filing  
8/23/2017Cynthia L. GoldenbergDirectorSell40,000$9.24$369,600.00View SEC Filing  
8/24/2016Don C StarkDirectorSell9,900$2.97$29,403.0055,848View SEC Filing  
8/23/2016Mary E PaetzoldDirectorSell15,000$2.98$44,700.0082,474View SEC Filing  
6/13/2016Cynthia L GoldenbergCEOSell371,990$3.03$1,127,129.70650,396View SEC Filing  
6/8/2016Cynthia L GoldenbergCEOSell41,441$3.62$150,016.42703,029View SEC Filing  
6/8/2016David M GoldenbergChairmanSell353,010$3.88$1,369,678.802,602,063View SEC Filing  
6/7/2016Cynthia L GoldenbergCEOSell4,600$4.01$18,446.00703,029View SEC Filing  
6/7/2016David M GoldenbergChairmanSell12,300$3.98$48,954.002,602,063View SEC Filing  
6/6/2016Cynthia L GoldenbergCEOSell63,959$4.09$261,592.31703,029View SEC Filing  
6/6/2016David M GoldenbergChairmanSell110,322$4.09$451,216.982,602,063View SEC Filing  
6/15/2015David M GoldenbergChairmanSell210,991$4.08$860,843.28View SEC Filing  
6/12/2015Brian A MarkisonDirectorSell5,564$4.22$23,480.08View SEC Filing  
6/12/2015David M GoldenbergChairmanSell359,653$4.32$1,553,700.96View SEC Filing  
6/9/2015Mary E PaetzoldDirectorSell4,677$4.60$21,514.20View SEC Filing  
6/5/2015Don C StarkDirectorSell5,732$4.14$23,730.48View SEC Filing  
12/11/2014Mary E PaetzoldDirectorSell10,000$4.71$47,100.00View SEC Filing  
12/9/2014Don C StarkDirectorSell5,500$4.51$24,805.00View SEC Filing  
9/13/2013Don StarkDirectorSell10,000$6.08$60,800.0022,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Immunomedics (NASDAQ IMMU) News Headlines

Source:
DateHeadline
 Brokerages Expect Immunomedics (IMMU) to Post -$0.15 EPS Brokerages Expect Immunomedics (IMMU) to Post -$0.15 EPS
www.americanbankingnews.com - May 22 at 5:23 AM
Immunomedics (IMMU) Receives Average Rating of "Buy" from AnalystsImmunomedics (IMMU) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 21 at 1:45 PM
Immunomedics (IMMU) Submits BLA for Sacituzumab Govitecan to US FDAImmunomedics (IMMU) Submits BLA for Sacituzumab Govitecan to US FDA
www.streetinsider.com - May 21 at 8:43 AM
Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The US Food and Drug ...Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The US Food and Drug ...
globenewswire.com - May 21 at 8:43 AM
BRIEF-Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The US FDABRIEF-Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The US FDA
www.reuters.com - May 21 at 8:43 AM
Immunomedics (IMMU) Upgraded by BidaskClub to "Buy"Immunomedics (IMMU) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - May 18 at 3:09 PM
Immunomedics lead ADC shows positive action in subgroup of treatment-resistant breast cancer patients; shares up 8% premarketImmunomedics' lead ADC shows positive action in subgroup of treatment-resistant breast cancer patients; shares up 8% premarket
seekingalpha.com - May 17 at 9:08 AM
Immunomedics (IMMU) option implied volatility into ASCOImmunomedics' (IMMU) option implied volatility into ASCO
www.streetinsider.com - May 17 at 8:59 AM
BRIEF-Immunomedics Announces Promising Data Of Sacituzumab Govitecan In Estrogen Receptor-Positive Metastatic ...BRIEF-Immunomedics Announces Promising Data Of Sacituzumab Govitecan In Estrogen Receptor-Positive Metastatic ...
www.reuters.com - May 17 at 8:59 AM
Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast ...Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast ...
globenewswire.com - May 17 at 8:59 AM
Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast CancerImmunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer
finance.yahoo.com - May 17 at 8:59 AM
Todays Research Reports on Trending Tickers: Immunomedics and Rite AidToday's Research Reports on Trending Tickers: Immunomedics and Rite Aid
finance.yahoo.com - May 17 at 8:59 AM
Immunomedics Target of Unusually Large Options Trading (IMMU)Immunomedics Target of Unusually Large Options Trading (IMMU)
www.americanbankingnews.com - May 17 at 8:15 AM
Immunomedics (IMMU) Upgraded to Hold at Zacks Investment ResearchImmunomedics (IMMU) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:45 PM
Jefferies Group Research Analysts Cut Earnings Estimates for Immunomedics (IMMU)Jefferies Group Research Analysts Cut Earnings Estimates for Immunomedics (IMMU)
www.americanbankingnews.com - May 14 at 5:11 AM
Immunomedics (IMMU) Announces  Earnings ResultsImmunomedics (IMMU) Announces Earnings Results
www.americanbankingnews.com - May 11 at 6:16 PM
BRIEF-Immunomedics Reports Q3 Loss Per Share $0.21BRIEF-Immunomedics Reports Q3 Loss Per Share $0.21
www.reuters.com - May 10 at 8:57 AM
Immunomedics, Inc. (IMMU) CEO Michael Pehl on Q3 2018 Results - Earnings Call TranscriptImmunomedics, Inc. (IMMU) CEO Michael Pehl on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:57 AM
Edited Transcript of IMMU earnings conference call or presentation 9-May-18 9:00pm GMTEdited Transcript of IMMU earnings conference call or presentation 9-May-18 9:00pm GMT
finance.yahoo.com - May 10 at 8:57 AM
Immunomedics: Fiscal 3Q Earnings SnapshotImmunomedics: Fiscal 3Q Earnings Snapshot
finance.yahoo.com - May 9 at 5:04 PM
Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate UpdateImmunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update
finance.yahoo.com - May 9 at 5:04 PM
Immunomedics (IMMU) Rating Lowered to Sell at Zacks Investment ResearchImmunomedics (IMMU) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 5 at 1:30 AM
Immunomedics (IMMU) Rating Lowered to Hold at BidaskClubImmunomedics (IMMU) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - May 5 at 12:29 AM
-$0.13 Earnings Per Share Expected for Immunomedics (IMMU) This Quarter-$0.13 Earnings Per Share Expected for Immunomedics (IMMU) This Quarter
www.americanbankingnews.com - May 4 at 9:21 PM
Immunomedics (IMMU) Upgraded by ValuEngine to "Strong-Buy"Immunomedics (IMMU) Upgraded by ValuEngine to "Strong-Buy"
www.americanbankingnews.com - May 3 at 10:34 PM
Immunomedics (IMMU) in Focus: Stock Moves 7.9% HigherImmunomedics (IMMU) in Focus: Stock Moves 7.9% Higher
www.zacks.com - May 1 at 8:54 AM
Today’s Research Reports on Stocks to Watch: Heat Biologics and ImmunomedicsToday’s Research Reports on Stocks to Watch: Heat Biologics and Immunomedics
finance.yahoo.com - May 1 at 8:54 AM
Immunomedics (IMMU) Given Average Rating of "Buy" by BrokeragesImmunomedics (IMMU) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 26 at 1:44 PM
Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+ ...Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+ ...
globenewswire.com - April 26 at 8:42 AM
Immunomedics (IMMU) Announces Oral Presentation of Sacituzumab Govitecan in HR+ mBC at ASCOImmunomedics (IMMU) Announces Oral Presentation of Sacituzumab Govitecan in HR+ mBC at ASCO
www.streetinsider.com - April 25 at 5:07 PM
Myriad Genetics (MYGN) & Immunomedics (IMMU) Critical ReviewMyriad Genetics (MYGN) & Immunomedics (IMMU) Critical Review
www.americanbankingnews.com - April 24 at 7:24 PM
Reader Inquiry: Is There Further Upside In Immunomedics?Reader Inquiry: Is There Further Upside In Immunomedics?
seekingalpha.com - April 23 at 8:38 AM
Immunomedics (IMMU) Upgraded at BidaskClubImmunomedics (IMMU) Upgraded at BidaskClub
www.americanbankingnews.com - April 20 at 11:39 AM
Immunomedics (IMMU) Rating Increased to Buy at Zacks Investment ResearchImmunomedics (IMMU) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 19 at 6:22 PM
Immunomedics (IMMU) Rating Lowered to Hold at Zacks Investment ResearchImmunomedics (IMMU) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:48 PM
 Brokerages Anticipate Immunomedics (IMMU) Will Announce Earnings of -$0.13 Per Share Brokerages Anticipate Immunomedics (IMMU) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - April 17 at 7:08 PM
When Will Immunomedics Inc (NASDAQ:IMMU) Become Profitable?When Will Immunomedics Inc (NASDAQ:IMMU) Become Profitable?
finance.yahoo.com - April 17 at 5:26 PM
BidaskClub Downgrades Immunomedics (IMMU) to BuyBidaskClub Downgrades Immunomedics (IMMU) to Buy
www.americanbankingnews.com - April 16 at 9:48 AM
Today’s Research Reports on Trending Tickers: Exact Sciences and ImmunomedicsToday’s Research Reports on Trending Tickers: Exact Sciences and Immunomedics
finance.yahoo.com - April 13 at 9:02 AM
Immunomedics (IMMU) Upgraded at ValuEngineImmunomedics (IMMU) Upgraded at ValuEngine
www.americanbankingnews.com - April 12 at 10:18 PM
Immunomedics (IMMU) Short Interest UpdateImmunomedics (IMMU) Short Interest Update
www.americanbankingnews.com - April 12 at 2:17 AM
Analyzing Intellia Therapeutics (NTLA) and Immunomedics (IMMU)Analyzing Intellia Therapeutics (NTLA) and Immunomedics (IMMU)
www.americanbankingnews.com - April 11 at 1:24 AM
Immunomedics (IMMU) Names Dr. Robert Iannone Head of Research & Development and CMOImmunomedics (IMMU) Names Dr. Robert Iannone Head of Research & Development and CMO
www.streetinsider.com - April 9 at 4:56 PM
Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical OfficerImmunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer
finance.yahoo.com - April 9 at 9:00 AM
Immunomedics, Inc. (IMMU) Given Consensus Recommendation of "Hold" by AnalystsImmunomedics, Inc. (IMMU) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 1 at 1:32 PM
 Brokerages Expect Immunomedics, Inc. (IMMU) Will Announce Earnings of -$0.13 Per Share Brokerages Expect Immunomedics, Inc. (IMMU) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - March 31 at 7:14 PM
Immunomedics (IMMU) Rating Lowered to Buy at BidaskClubImmunomedics (IMMU) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - March 26 at 9:55 AM
Immunomedics (IMMU) Lifted to "Hold" at ValuEngineImmunomedics (IMMU) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - March 25 at 5:22 PM
Immunomedics (IMMU) Cut to "Hold" at BidaskClubImmunomedics (IMMU) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 17 at 12:05 PM
 Analysts Expect Immunomedics, Inc. (IMMU) to Announce -$0.13 EPS Analysts Expect Immunomedics, Inc. (IMMU) to Announce -$0.13 EPS
www.americanbankingnews.com - March 14 at 5:24 PM

SEC Filings

Immunomedics (NASDAQ:IMMU) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Immunomedics (NASDAQ:IMMU) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Immunomedics (NASDAQ IMMU) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.